We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Prognostic Roles of Pretreatment Circulating Tumor Cells, Circulating Cancer Stem-Like Cells, and Programmed Cell Death-1 Expression on Peripheral Lymphocytes in Patients with Initially Unresectable, Recurrent or Metastatic Head and Neck Cancer: An Exploratory Study of Three Biomarkers in One-time Blood Drawing
- Authors
Chang, Pei-Hung; Wu, Min-Hsien; Liu, Sen-Yu; Wang, Hung-Ming; Huang, Wen-Kuan; Liao, Chun-Ta; Yen, Tzu-Chen; Ng, Shu-Hang; Chen, Jen-Shi; Lin, Yung-Chang; Lin, Hung-Chih; Hsieh, Jason Chia-Hsun
- Abstract
Circulating tumor cells (CTCs) and immune status are strongly related to cancer prognosis, although few studies have examined both factors. This prospective observational study (ClinicalTrials.gov : NCT02420600) evaluated whether CTCs, circulating cancer stem-like cells (cCSCs), and peripheral lymphocytes with/without Programmed cell death protein 1 (PD-1) expression were associated with prognosis among patients receiving palliative chemotherapy for initially unresectable, recurrent/metastatic head and neck squamous cell carcinoma (rmHNSCC). Thirty-four patients were enrolled between January 2015 and June 2016. Overall survival (OS) was associated with a higher CTC number (hazard ratio [HR]: 1.01, p = 0.0004) and cCSC ratio (HR: 29.903, p < 0.0001). Progression-free survival (PFS) was also associated with CTC number (HR: 1.013, p = 0.002) and cCSC ratio (HR: 10.92, p = 0.003). A CD8+ proportion of ≥ 17% was associated with improved OS (HR: 0.242, p = 0.004). A CD4: CD8 ratio of >1.2 was associated with poorer trend of PFS (HR: 2.12, p = 0.064). PD-1 expression was not associated with survival outcomes. Baseline CTCs, cCSC ratio, and CD8+ ratio may predict prognosis in rmHNSCC.
- Subjects
LYMPHOCYTES; APOPTOSIS; BLOOD testing; BLOOD circulation; CANCER patient psychology; CANCER relapse; LONGITUDINAL method; HEAD tumors; METASTASIS; SCIENTIFIC observation; NECK tumors; RESEARCH; STEM cells; SURVIVAL analysis (Biometry); TUMOR markers; DESCRIPTIVE statistics; CD4 lymphocyte count; SURGERY; PROGNOSIS; PHYSIOLOGY
- Publication
Cancers, 2019, Vol 11, Issue 4, p540
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers11040540